Cutting edge: Genetic variation in TLR1 is associated with Pam3CSK4-induced effector T cell resistance to regulatory T cell suppression

Journal of Immunology

Volumn 193, Issue 12, 2014, Pages 5786-5790

  Mikacenic, Carmen ^a   Schneider, Anya ^b   Radella, Frank ^a   Buckner, Jane H ^b   Wurfel, Mark M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; LIPOPEPTIDE; PEPTIDE PAM3CSK4; STAT3 PROTEIN; TOLL LIKE RECEPTOR 1; UNCLASSIFIED DRUG; PAM(3)CSK(4) PEPTIDE;

ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; ALLELE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL MEMBRANE; DRUG EFFECTS; GENETIC VARIATION; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE SUBPOPULATION;

ALLELES; CELL MEMBRANE; GENETIC VARIATION; HAPLOTYPES; HUMANS; IMMUNOMODULATION; INTERLEUKIN-6; LIPOPEPTIDES; POLYMORPHISM, SINGLE NUCLEOTIDE; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTOR 1;

EID: 84916919275     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401185     Document Type: Article

References (20)

1. Akira, S., K. Takeda, and T. Kaisho. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2: 675-680.
2. Takeuchi, O., S. Sato, T. Horiuchi, K. Hoshino, K. Takeda, Z. Dong, R. L. Modlin, and S. Akira. 2002. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol. 169: 10-14.
3. Takeuchi, O., T. Kawai, P. F. Mühlradt, M. Morr, J. D. Radolf, A. Zychlinsky, K. Takeda, and S. Akira. 2001. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int. Immunol. 13: 933-940.
4. Guan, Y., D. R. E. Ranoa, S. Jiang, S. K. Mutha, X. Li, J. Baudry, and R. I. Tapping. 2010. Human TLRs 10 and 1 share common mechanisms of innate immune sensing but not signaling. J. Immunol. 184: 5094-5103.
5. Mayerle, J., C. M. den Hoed, C. Schurmann, L. Stolk, G. Homuth, M. J. Peters, L. G. Capelle, K. Zimmermann, F. Rivadeneira, S. Gruska, et al. 2013. Identification of genetic loci associated with Helicobacter pylori serologic status. [Published erratum appears in 2013 JAMA 310: 99.] JAMA 309: 1912-1920.
6. Hinds, D. A., G. McMahon, A. K. Kiefer, C. B. Do, N. Eriksson, D. M. Evans, B. St Pourcain, S. M. Ring, J. L. Mountain, U. Francke, et al. 2013. A genome-wide association meta-analysis of self-reported allergy identifies shared and allergy-specific susceptibility loci. Nat. Genet. 45: 907-911.
7. Bønnelykke, K., M. C. Matheson, T. H. Pers, R. Granell, D. P. Strachan, A. C. Alves, A. Linneberg, J. A. Curtin, N. M. Warrington, M. Standl, et al. 2013. Meta-analysis of genome-wide association studies identifies ten loci influencing allergic sensitization. Nat. Genet. 45: 902-906.
8. Heffelfinger, C., A. J. Pakstis, W. C. Speed, A. P. Clark, E. Haigh, R. Fang, M. R. Furtado, K. K. Kidd, and M. P. Snyder. 2014. Haplotype structure and positive selection at TLR1. Eur. J. Hum. Genet. 22: 551-557.
9. Wurfel, M. M., A. C. Gordon, T. D. Holden, F. Radella, J. Strout, O. Kajikawa, J. T. Ruzinski, G. Rona, R. A. Black, S. Stratton, et al. 2008. Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am. J. Respir. Crit. Care Med. 178: 710-720.
10. Johnson, C. M., E. A. Lyle, K. O. Omueti, V. A. Stepensky, O. Yegin, E. Alpsoy, L. Hamann, R. R. Schumann, and R. I. Tapping. 2007. Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J. Immunol. 178: 7520-7524.
11. Hart, B. E., and R. I. Tapping. 2012. Cell surface trafficking of TLR1 is differentially regulated by the chaperones PRAT4A and PRAT4B. J. Biol. Chem. 287: 16550-16562.
12. Mikacenic, C., A. P. Reiner, T. D. Holden, D. A. Nickerson, and M. M. Wurfel. 2013. Variation in the TLR10/TLR1/TLR6 locus is the major genetic determinant of interindividual difference in TLR1/2-mediated responses. Genes Immun. 14: 52-57.
13. Hawn, T. R., E. A. Misch, S. J. Dunstan, G. E. Thwaites, N. T. N. Lan, H. T. Quy, T. T. H. Chau, S. Rodrigues, A. Nachman, M. Janer, et al. 2007. A common human TLR1 polymorphism regulates the innate immune response to lipopeptides. Eur. J. Immunol. 37: 2280-2289.
14. Oberg, H.-H., T. T. H. Ly, S. Ussat, T. Meyer, D. Kabelitz, and D. Wesch. 2010. Differential but direct abolishment of human regulatory T cell suppressive capacity by various TLR2 ligands. J. Immunol. 184: 4733-4740.
15. Nyirenda, M. H., L. Sanvito, P. J. Darlington, K. O'Brien, G.-X. Zhang, C. S. Constantinescu, A. Bar-Or, and B. Gran. 2011. TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function. J. Immunol. 187: 2278-2290.
16. Schneider, A., and J. H. Buckner. 2011. Assessment of suppressive capacity by human regulatory T cells using a reproducible, bi-directional CFSE-based in vitro assay. Methods Mol. Biol. 707: 233-241.
17. Schneider, A., M. Rieck, S. Sanda, C. Pihoker, C. Greenbaum, and J. H. Buckner. 2008. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J. Immunol. 181: 7350-7355.
18. Pasare, C., and R. Medzhitov. 2003. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299: 1033-1036.
19. Goodman, W. A., A. D. Levine, J. V. Massari, H. Sugiyama, T. S. McCormick, and K. D. Cooper. 2009. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J. Immunol. 183: 3170-3176.
20. Schneider, A., S. A. Long, K. Cerosaletti, C. T. Ni, P. Samuels, M. Kita, and J. H. Buckner. 2013. In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6 - mediated signaling. Sci. Transl. Med. 5: 170ra15.